Browse DPPA2

Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF14047 Dppa2/4 conserved region
PF14049 Dppa2/4 conserved region in higher vertebrates
Function

Binds to target gene promoters, including NKX2-5 and SYCE1, but not GATA4, and may be involved in the maintenance of the active epigenetic status of these genes.

> Gene Ontology
 
Biological Process GO:0006479 protein methylation
GO:0008213 protein alkylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0019827 stem cell population maintenance
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0031056 regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0032259 methylation
GO:0043414 macromolecule methylation
GO:0060484 lung-associated mesenchyme development
GO:0060485 mesenchyme development
GO:0060541 respiratory system development
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0098727 maintenance of cell number
GO:1902275 regulation of chromatin organization
GO:2000648 positive regulation of stem cell proliferation
Molecular Function GO:0003682 chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DPPA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between DPPA2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18519755Non-Small Cell Lung CarcinomaPromote immunityThe restricted expression in normal tissues, expression in tumors with coexpression of CTAs, and spontaneous immunogenicity indicate that ECSA/DPPA2 is a promising target for antigen-specific immunotherapy in NSCLC.
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DPPA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DPPA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0640.784
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0690.91
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0540.895
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0420.955
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3240.772
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5130.688
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0910.83
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0910.886
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1110.65
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DPPA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DPPA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DPPA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DPPA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DPPA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DPPA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DPPA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDPPA2
Namedevelopmental pluripotency associated 2
Aliases PESCRG1; CT100; cancer/testis antigen 100; ECAT15-2; embryonic stem cell (ESC) associated transcript 15-2; p ......
Chromosomal Location3q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DPPA2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.